SecBot SecBot
PREM14A ·Filed May 29, 2026

ESPR

Esperion Therapeutics, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed5mo ago SEC0001104659-26-068371
Preliminary proxy statement (merger-related)
Actionable Insight ▲ Bullish

The premium and deal structure suggest the stock should trade near the $3.16 cash consideration (adjusted for time value and deal risk) pending shareholder vote. CVR value is highly contingent on commercial milestones for NEXLETOL/NEXLIZET and ENBUMYST. Monitor proxy solicitation results and regulatory HSR clearance. Spread widening could present an arbitrage entry, but CVR complexity and uncertainty around milestone achievement add risk.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$3.13
T+0 close · May 29, 2026 · via day close
Latest settled
+0.96%
T+20 · $3.16
Vs SPY
+2.26%
α at T+20
Next horizon
T+60
due 3mo ago
  1. T+0 · Jun 1 $3.13entry
  2. T+1 · 6mo ago +0.32%α +0.17% · $3.14
  3. T+5 · 5mo ago 0.00%α +2.75% · $3.13
  4. T+20 · 5mo ago +0.96%α +2.26% · $3.16
  5. T+60 · due 3mo ago Pending

Price Chart

Loading chart...

Executive Summary

Esperion Therapeutics has filed a preliminary proxy statement (PREM14A) for its acquisition by an affiliate of ArchiMed SAS. Stockholders will receive $3.16 per share in cash plus one contingent value right (CVR) per share, with potential milestone payments of up to $100M in aggregate tied to U.S. net sales milestones. The Board unanimously recommends approval. Total transaction value is approximately $1.08 billion including debt financing. The special meeting to vote on the merger is expected in Q3 2026.

Key Financial Metrics

Deal Value
$1.1B
Premium
58%
Deal Type
merger

Key Facts

  • Stockholders to receive $3.16 per share in cash plus one CVR per share
  • CVR provides potential additional payments: up to $40M tied to bempedoic acid products' 2027 U.S. net sales exceeding $300M-$350M, and up to $60M tied to ENBUMYST U.S. net sales of $160M+ in any single calendar year through 2030
  • Total financing of approximately $1.08 billion: $706.1M equity commitment and $550M debt commitment ($400M funded at close)
  • Cash consideration represents ~58% premium to $2.00 closing price on April 30, 2026
  • Board unanimously recommends FOR the merger; Centerview Partners rendered fairness opinion
  • Merger expected to close in Q3 2026, subject to stockholder vote, HSR, and German antitrust approval

Financial Impact

Clear premium to unaffected price. $3.16/share cash plus CVR with up to $0.32/share at maximum milestone payout, or an illustrative risk-adjusted NPV of $0.15/share.

acquisition premiumshare price

Risk Factors

  • Failure to obtain stockholder approval for merger
  • Regulatory delays or failure to obtain HSR/German antitrust clearance
  • Potential for superior proposal triggering termination fee ($34.2M)
  • CVR milestones may not be achieved, leaving only $3.16/share
  • Post-merger debt burden (~$400M at close) on operating performance

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
79% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
PREM14A Filing (Primary)0001104659-26-068371
Document: tm2615754d1_ex-filingfees.htm0001104659-26-068371
Document: 0001104659-26-068371-index-headers.html0001104659-26-068371
Document: 0001104659-26-068371-index.html0001104659-26-068371
Document: 0001104659-26-068371.txt0001104659-26-068371

Track record

21 reports on ESPR

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
  2. Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
  3. Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
  4. Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
  5. Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
  6. Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
  7. Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
  8. Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
  9. Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
  10. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 29, 2026